Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244947 | 0.90 | FFAR4 (0.37) | FFAR4FFAR1S1PR1S1PR3SGPL1 | |
| SCHEMBL2247448 | 0.85 | FFAR4 (0.38) | FFAR4FFAR1ITGB3ITGA2B | |
| SCHEMBL2244276 | 0.82 | P2RY6 (0.34) | P2RY6 | |
| SCHEMBL2244283 | 0.82 | P2RY6 (0.34) | P2RY6 | |
| SCHEMBL2250158 | 0.74 | CA1 (0.51) | — | |
| SCHEMBL2246402 | 0.74 | RXRA (0.41) | — | |
| SCHEMBL2247648 | 0.71 | AR (0.36) | — | |
| SCHEMBL2250878 | 0.70 | P2RY6 (0.39) | P2RY6 | |
| SCHEMBL2247705 | 0.69 | HPGD (0.40) | P2RY6 | |
| SCHEMBL2244057 | 0.69 | STS (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | FFAR4 107/4885FFAR1 132/4885S1PR1 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.